David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Leukemia

Myelodysplastic Syndromes

Mikkael A. Sekeres, MD

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses an additional analysis of a phase II study of azacitidine combined with lenalidomide or with vorinostat vs azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia (Abstract 908).

Lymphoma

Andrew J. Davies, MRCP, PhD

Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results

Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).

Lymphoma

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data (Abstract 254).

Feb

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Mikkael A. Sekeres, MD, on MDS and CMML Study Results: SWOG S1117

Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

Oncolytic Virus Triggers Immune System Against Glioblastoma Cells

Adjuvant Durvalumab in Resected Early-Stage NSCLC

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products

Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk